| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.0029 | 1 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | -0.00092 | 1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00098 | 1 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.00093 | 1 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.00042 | 1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.00038 | 1 |